150
Participants
Start Date
August 19, 2020
Primary Completion Date
July 31, 2026
Study Completion Date
July 31, 2027
Testosterone cypionate
Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
Enzalutamide
Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
Testosterone enanthate
Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
RECRUITING
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RECRUITING
University of Minnesota, Minneapolis
RECRUITING
University of Nebraska Medical Center, Omaha
RECRUITING
University of California, San Diego (UCSD), San Diego
RECRUITING
University of Washington/Fred Hutchinson Cancer Center, Seattle
RECRUITING
Dana-Faber Cancer Institute, Boston
United States Department of Defense
FED
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER